Gilead (GILD) stock and Vertex Pharma (VRTX) stock are said to be relatively immune to Trump administration's tariffs threats ...

New research from Bayes Business School, in collaboration with biopharmaceuticals company Merck KGaA, suggests member states ...

Just as a new growth phase seemed to be inching closer, European manufacturing is now facing a new era of trade turmoil. A ...

The FTSE 100 (^FTSE) and European stocks were mixed on Thursday amid reports that the Trump administration has reached out to ...

Trade deals with the US and other countries may offset some of the impact of US tariffs. In the meantime, diversifying to ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

Pre-Clinical Drug Discovery Services Market to grow through 2035, driven by rising chronic diseases and increased outsourcing of early-stage R&D.

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...